Development of novel mixed-ligand oxotechnetium [SNS/S] complexes as potential 5-HT1A receptor imaging agents.
The "3 + 1" ligand system [SN(R)S/S combination] was applied in order to synthesize neutral mixed-ligand oxotechnetium complexes of the general formula 99mTcO[SN(R)S]/[S] as potential 5-HT1A receptor imaging agents. The complexes are carrying the 1-(2-methoxyphenyl)piperazine moiety, a fragment of the true 5-HT1A antagonist WAY 100635, either on the monodentate ligand [S] or on the tridentate ligand [SN(R)S]. The complexes MO[EtN(CH2CH2S)2] [o-MeOC6H4N(CH2CH2)2NCH2CH2S] (3), MO[o- MeOC6H4N(CH2CH2)2N(CH2)3N(CH2CH2S)2][PhS] (6) and MO[o-MeOC6H4N(CH2CH2)2N(CH2)3N(CH2CH2S)2] [PhCH2CH2S] (9), where M = 99mTc, were prepared at tracer level using 99mTc glucoheptonate as precursor. For structural characterization, the analogous oxorhenium (M = Re, 1, 4 and 7, respectively) and oxotechnetium (M = 99gTc, 2, 5 and 8, respectively) complexes were prepared by ligand exchange reactions. All products were characterized by elemental analysis and spectroscopic methods. Complexes 1, 4 and 7 were further characterized by crystallographic analysis. For 1, the coordination geometry about rhenium can be described as trigonally distorted square pyramidal (tau = 0.36), while for 4 and 7, as distorted trigonal bipyramidal (tau = 0.66 and tau = 0.61, respectively). The coordination sphere about oxorhenium in all complexes is defined by the SNS donor atom set of the tridentate ligand and the sulfur atom of the monodentate coligand. The structure of the 99mTc complexes 3, 6 and 9 was established by comparative HPLC using authentic oxorhenium and oxotechnetium samples. The binding affinity of oxorhenium compounds for the 5-HT1A receptor subtype was determined in rat brain hippocampal preparations (IC50 = 6-31 nM). Preliminary tissue distribution data in healthy mice revealed the ability of all three 99mTc complexes to cross the intact blood-brain barrier (0.49-1.15% ID at 1 min p.i.). In addition, complexes 6 and 9 showed significant brain retention. These promising results have demonstrated that the SNS/S mixed-ligand system can be used in the development of 99mTc complexes as potential 5-HT1A receptor imaging agents.
Papagiannopoulou
D
D
Institute of Radioisotopes-Radiodiagnostic Products, National Centre for Scientific Research Demokritos, 15310 Ag. Paraskevi, Athens, Greece.
Pirmettis
I
I
Maina
T
T
Pelecanou
M
M
Nikolopoulou
A
A
Chiotellis
E
E
Raptopoulou
C P
CP
Vlahos
A T
AT
Terzis
A
A
Papadopoulos
M
M
Chiotellis
E
E
D000818:Animals; D001667:Binding, Competitive; D015392:Chemistry, Inorganic / Q000379:methods; D006624:Hippocampus / Q000378:metabolism; D020128:Inhibitory Concentration 50; D008297:Male; D051379:Mice; D015394:Molecular Structure; D015609:Organotechnetium Compounds / Q000737:chemistry* / Q000378:metabolism* / Q000493:pharmacokinetics; D010879:Piperazines / Q000737:chemistry; D011725:Pyridines / Q000737:chemistry; D051381:Rats; D017208:Rats, Wistar; D011985:Receptors, Serotonin / Q000378:metabolism*; D044263:Receptors, Serotonin, 5-HT1; D012211:Rhenium / Q000737:chemistry; D013329:Structure-Activity Relationship; D013400:Sugar Acids / Q000737:chemistry; D017556:Technetium Compounds / Q000737:chemistry; D014018:Tissue Distribution; D015899:Tomography, Emission-Computed, Single-Photon / Q000379:methods*
D015609:Organotechnetium Compounds; D010879:Piperazines; D011725:Pyridines; D011985:Receptors, Serotonin; D044263:Receptors, Serotonin, 5-HT1; D013400:Sugar Acids; D017556:Technetium Compounds; C436378:oxo(N,N-bis(2-thioethyl)-3-(4-(2-methoxyphenyl)piperazin-1-yl)propylamine)(phenylthio)technetium; C436379:oxo(N,N-bis(2-thioethyl)-3--(4-(2-methoxyphenyl)piperazin-1-yl)propylamine)(phenylethylthio)technetium; C090413:N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide; D012211:Rhenium; C100014:technetium Tc 99m gluceptate